Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. - sprookjes - yvandenbroek - TriplyDB

Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.

Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.

http://www.wikidata.org/entity/Q33419859

about

The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections Advances in bacteriophage-mediated control of plant pathogens Bacteriophage Procurement for Therapeutic Purposes Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections Phage cocktails and the future of phage therapy Bacteriophages and phage-derived proteins--application approaches Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus Strain Specific Phage Treatment for Staphylococcus aureus Infection Is Influenced by Host Immunity and Site of Infection Application of Bacteriophage-containing Aerosol against Nosocomial Transmission of Carbapenem-Resistant Acinetobacter baumannii in an Intensive Care Unit Bacteriophage therapy of a Vibrio parahaemolyticus infection caused by a multiple-antibiotic-resistant O3:K6 pandemic clinical strain.Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applications Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany Phage therapy--constraints and possibilities.Characterization of JG024, a pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions.Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.Characterization, sequencing and comparative genomic analysis of vB_AbaM-IME-AB2, a novel lytic bacteriophage that infects multidrug-resistant Acinetobacter baumannii clinical isolates Contrasted coevolutionary dynamics between a bacterial pathogen and its bacteriophages.Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus Bacteriophages of Pseudomonas.Genomic and proteomic characterization of the broad-host-range Salmonella phage PVP-SE1: creation of a new phage genus.Phage treatment of human infections.CIM(®) monolithic anion-exchange chromatography as a useful alternative to CsCl gradient purification of bacteriophage particles.Isolation and partial characterization of bacteriophages infecting Pseudomonas syringae pv. actinidiae, causal agent of kiwifruit bacterial canker.Experimental phage therapy of burn wound infection: difficult first steps Evolution of Pseudomonas aeruginosa virulence as a result of phage predation.Genomic characterization of JG068, a novel virulent podovirus active against Burkholderia cenocepacia.Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies Population dynamics of a Salmonella lytic phage and its host: implications of the host bacterial growth rate in modelling Removal of endotoxins from bacteriophage preparations by extraction with organic solvents.Characterization of newly isolated lytic bacteriophages active against Acinetobacter baumannii.Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against Pseudomonas aeruginosa Biofilm.The isolation and characterization of two Stenotrophomonas maltophilia bacteriophages capable of cross-taxonomic order infectivity.In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining?Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos.Phage ΦPan70, a Putative Temperate Phage, Controls Pseudomonas aeruginosa in Planktonic, Biofilm and Burn Mouse Model Assays Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15 A Partially Purified Acinetobacter baumannii Phage Preparation Exhibits no Cytotoxicity in 3T3 Mouse Fibroblast Cells.

P2860

Q21131311-4825DE7A-61BC-463A-919F-EDF3447BD264 Q21296665-121E2DA4-D000-4EDE-A30E-4D78B292B5EE Q26738479-803CDD3D-A47A-40DC-BF76-82C544E2C6C1 Q26799417-9532D90F-5BE5-4390-A995-12A35D1036F6 Q26823401-E51B95E3-1045-48F6-910B-64C5DE9F3EA2 Q26995797-904674BC-BCF1-4982-A3A4-46290D6E1766 Q28082731-D656CB30-8A49-48CE-B8B7-634C8D3889FB Q28484466-FA8A3533-F69C-443B-A24B-740252ECF812 Q28485429-F2503ED5-73CD-41BB-8381-CFD476561472 Q28546694-B57A60CA-D3C9-4828-BA0A-555A404475C0 Q28555082-B0B576EC-5977-4B87-92F7-F91E08F25127 Q30359301-99E9D8E1-2C7A-4023-B001-D9A30CDA4B27 Q30585271-9FD32CE0-9A9B-40D8-826A-F77C6AA6C964 Q33405088-3AAB227E-7007-407D-98EC-5CCE570801DF Q33667556-B76367AD-9200-433F-98C6-D75D6C3F9030 Q33756667-4883CD32-95D5-4021-B260-A4FEB9445F0B Q33798541-CE1901FA-9863-4596-8E75-5501E916C3D9 Q33890690-B09D4C3C-D356-452B-A694-FCCC6B5870AA Q34002414-09758BCB-3F31-4F77-AD1A-0627537BE945 Q34023508-CA241324-604F-48FA-8F4C-1A0416DDA14F Q34126072-E58056BF-DCA1-444F-A9C0-070395673C2E Q34210551-69EAA451-DF7F-42AC-A12F-3106A415554E Q34254407-D8DDDEBC-B72D-49B6-B572-D85627CC52F8 Q34306994-21F575E3-40F6-47DA-BB09-5DCD92A92A7A Q34419366-32BA4D63-CD03-40E1-92AD-85466F315FD4 Q34420348-8BD280A9-D84B-4E01-A2BE-484A25F2E474 Q34871061-AF244DA3-BE1B-4A4D-8C59-342FB00A169F Q34974472-CD1FDCA9-6A83-4DD1-8006-73B4F37A3048 Q34999578-FC0A9B81-65BB-4DF7-B2B9-4CE5A7C9E85A Q35211072-56263194-ED94-4D28-B992-B5F02055118F Q35219507-8B76BF5B-07F2-4C4D-9A1E-18E4546EA90B Q35222732-013054E1-9082-46DD-908B-D97AE69EB14C Q35634231-46D4B976-F02A-45C6-9BC5-E30E76E140C8 Q35763512-7B652C06-987F-4953-9AA7-5DFB4C5044CE Q35780029-AC386FD1-A828-4E27-A39C-9B9B6FE9836D Q35878716-8B48A0D6-3CD0-40E2-A5F8-EAA441B7D47A Q35963673-1CA3AAC3-4341-4E1E-9CC8-BA3C541D7089 Q36076253-0A4E891D-1768-4DA8-85E4-1A6FC23269C8 Q36086395-230157EC-1E8E-470D-BB89-D2940160673C Q36106493-BE3A4452-F69F-4B8F-B605-3038E5E09A69

P2860

Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.

http://www.wikidata.org/entity/Q33419859

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Quality-controlled small-scale ...... use in human clinical trials.

@ast

Quality-controlled small-scale ...... use in human clinical trials.

@en

type

label

Quality-controlled small-scale ...... use in human clinical trials.

@ast

Quality-controlled small-scale ...... use in human clinical trials.

@en

prefLabel

Quality-controlled small-scale ...... use in human clinical trials.

@ast

Quality-controlled small-scale ...... use in human clinical trials.

@en

P1433

Q33419859-F4DED867-F7C6-4D6E-ACF9-F5C574828C21

P1476

Q33419859-FA668102-823B-4BAD-895A-6FCDF390DE1F

P2093

Q33419859-0C412ADF-6349-4275-A786-BB7832C77AA6

Q33419859-2A9771B5-5EA4-4D08-BC7B-699E2DEC6249

Q33419859-4FBA605A-F10F-45B2-9294-C613581F8F0D

Q33419859-7C77B16F-2FB6-4937-B593-BFC97E1EC869

Q33419859-834E1146-85BF-4806-AF32-66E4F3024BD4

Q33419859-887488F4-0BE7-4798-BDD9-BBD6A342CACC

Q33419859-9478ED72-8480-4D0D-AC98-540823177762

Q33419859-9793D18A-0043-4408-B919-7BB124CD9285

Q33419859-AD82A4E8-C24F-4937-983C-BA253AEC3EA1

Q33419859-B024ADC8-3642-4AC5-B843-B6669F9F141B

P2860

Q33419859-004ED877-7453-4402-B537-12C630CE394E

Q33419859-04DE0FA4-1724-43EB-BCC4-FE3E0DFCD58A

Q33419859-25803F3E-4E80-492C-A296-A6BC4013620C

Q33419859-4479FED4-DE91-4461-81F5-AA063A3495CE

Q33419859-4DE9006F-7529-4D16-8CE9-BB209C165AB9

Q33419859-53F83284-CF6D-4CF0-98F1-FDEFE7A02C9F

Q33419859-579117D1-4C4A-4FB3-BB05-74D021B0F8FD

Q33419859-5D0FFA26-3C83-488E-8D53-F28D1D18C3A3

Q33419859-66C7D361-63F3-4734-A35A-3C2A4BCFE072

Q33419859-71258FFC-B195-4753-98A1-7863E1670875

P304

Q33419859-84C4B776-21BA-4446-AEAD-3C018E9F277C

P31

Q33419859-32ABE7F6-29F9-4C16-90CD-6FBCD0F2B302

P356

Q33419859-E76EE7B7-4C66-4A7E-A501-21D724BD986C

P407

Q33419859-8A8A573B-0152-4866-A38C-F9AC19A977D7

P433

Q33419859-148A2210-3AAE-4742-BE15-B423F5ACA730

P478

Q33419859-6924437A-95F1-4AF6-BA28-B7CBB79DB37C

P50

Q33419859-43A7754B-0A6D-4388-A02E-A53785D83F01

Q33419859-955915F8-4183-41C7-A490-229A1E605EA5

Q33419859-DAA9770A-7829-4B1E-9485-0447C9DC83DA

Q33419859-E699EB46-F87F-492A-9F5D-9CBA3E7A3256

P577

Q33419859-E7834814-DD86-42C6-BEA6-EC55FCF8BD4D

P5875

Q33419859-60F918AC-E3C7-4ADE-AFF8-C926BBDD9C00

P698

Q33419859-BC005C91-C961-4BC3-890F-EF7F2EE02149

P921

Q33419859-9CA8BE10-FCBA-4584-9429-23AA6F327B3B

P932

Q33419859-6CCC7345-E174-4D7E-9DCF-7F227D9338FA

P356

JOURNAL.PONE.0004944

P1433

P1476

Quality-controlled small-scale ...... use in human clinical trials.

@en

P2093

Daniel De Vos

http://www.w3.org/2001/XMLSchema#string

Gilbert Verbeken

http://www.w3.org/2001/XMLSchema#string

Guido Volckaert

http://www.w3.org/2001/XMLSchema#string

Gunther Verween

http://www.w3.org/2001/XMLSchema#string

Jan Mast

http://www.w3.org/2001/XMLSchema#string

Luc Van Parys

http://www.w3.org/2001/XMLSchema#string

Marina Tediashvili

http://www.w3.org/2001/XMLSchema#string

Martin Zizi

http://www.w3.org/2001/XMLSchema#string

Maya Merabishvili

http://www.w3.org/2001/XMLSchema#string

Nino Lashkhi

http://www.w3.org/2001/XMLSchema#string

P2860

Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model

Genomic analysis of Pseudomonas aeruginosa phages LKD16 and LKA1: establishment of the phiKMV subgroup within the T7 supergroup

Antibacterial resistance worldwide: causes, challenges and responses

Digitized fluorescent RFLP analysis (fRFLP) as a universal method for comparing genomes of culturable dsDNA viruses: application to bacteriophages.

Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.

Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium.

The prospect for bacteriophage therapy in Western medicine.

The genome of bacteriophage phiKMV, a T7-like virus infecting Pseudomonas aeruginosa.

Comparative genomic analysis of 18 Pseudomonas aeruginosa bacteriophages.

Burn wound infections.

P304

e4944

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0004944

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Mario Vaneechoutte

Jean-Paul Pirnay

Nina Chanishvili

P577

2009-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24214261

http://www.w3.org/2001/XMLSchema#string

P698

19300511

http://www.w3.org/2001/XMLSchema#string

P921

P932

2654153

http://www.w3.org/2001/XMLSchema#string